Poor Response to Ovulation Induction

1
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
1
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Genesis Therapeutics
Genesis TherapeuticsCA - Burlingame
1 program
1
Autologous platelet rich plasmaPhase 2/31 trial
Active Trials
NCT05181748RecruitingEst. Jan 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Genesis TherapeuticsAutologous platelet rich plasma

Clinical Trials (1)

NCT05181748Genesis TherapeuticsAutologous platelet rich plasma

Autologous Platelet Rich Plasma Intraovarian Infusion for Poor Responders

Start: Jan 2019Est. completion: Jan 2026
Phase 2/3Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials
1 companies competing in this space